Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
11.19
-0.14 (-1.24%)
At close: Mar 30, 2026, 4:00 PM EDT
11.27
+0.08 (0.71%)
After-hours: Mar 30, 2026, 5:02 PM EDT

Trevi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,4371,6063869211622
Market Cap Growth
155.60%316.55%321.47%-20.91%418.86%-50.32%
Enterprise Value
1,2491,419278.779.56-2.67-5.86
Last Close Price
11.1912.524.121.341.930.78
PE Ratio
--39.12-8.77-4.62-4.29-0.52
PB Ratio
7.848.773.871.111.081.31
P/TBV Ratio
8.229.214.221.611.161.05
P/FCF Ratio
--38.16-10.07-2.87-4.08-0.77
P/OCF Ratio
--38.17-10.08-2.89-4.11-0.77
EV/EBITDA Ratio
--28.84-5.43-0.280.090.18
EV/EBIT Ratio
--28.76-5.41-0.280.090.18
EV/FCF Ratio
--33.69-7.28-0.300.090.20
Debt / Equity Ratio
0.000.000.010.010.020.51
Debt / EBITDA Ratio
-0.01-0.01-0.02-0.04-0.31-0.45
Debt / FCF Ratio
-0.02-0.02-0.03-0.04-0.32-0.50
Net Debt / Equity Ratio
-1.02-1.02-1.07-0.99-1.04-1.30
Net Debt / EBITDA Ratio
3.813.812.082.423.730.69
Net Debt / FCF Ratio
4.454.452.782.563.930.77
Quick Ratio
19.3119.3110.2414.258.992.89
Current Ratio
19.6619.6610.4115.039.152.98
Return on Equity (ROE)
-30.23%-30.23%-52.59%-30.59%-46.82%-153.03%
Return on Assets (ROA)
-32.37%-32.37%-51.41%-31.97%-37.08%-75.92%
Return on Invested Capital (ROIC)
878.81%878.83%1707.29%2297.72%674.26%780.78%
Return on Capital Employed (ROCE)
-34.73%-34.73%-56.01%-35.12%-44.19%-96.47%
Earnings Yield
-2.98%-2.56%-11.41%-21.64%-23.32%-190.49%
FCF Yield
-2.93%-2.62%-9.93%-34.81%-24.49%-129.82%
Buyback Yield / Dilution
-32.14%-32.14%-2.97%-53.44%-182.56%-26.48%
Total Shareholder Return
-32.14%-32.14%-2.97%-53.44%-182.56%-26.48%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q